Cloning a Chow Chow will be easy and will also cost at least half of what it would cost to clone any other type of dog, announced a South Korean biotech company today while presenting new cloning technology.
But dog-owners – who pay 100,000 dollars or more to clone a pet – will still have to pay tens of thousands of dollars if they want to clone their beloved four-legged friends, and must be prepared for long waiting-lists, because most cloning at a commercial level involves dogs used for work, like police dogs used in airports.
The Rnl Bio company announced
South Korea’s government drug agency cleared the way Thursday for commercial sales of what it called the world’s first approved medicine using stem cells collected from other people.
Cartistem, developed by Seoul-based Medipost, will help regenerate knee cartilage using stem cells developed from newborns’ umbilical cord blood, the Korea Food and Drug Administration said.
“Cartistem is… the world’s first approved allogeneic (taken from different individuals of the same species) stem cell drug, that can offer new opportunity for treatment of patients with degenerative arthritis,” the administration said in a statement.
Medipost said 27 billion won ($23.8 million) from private investors and government